Andrew Silver Named CFO at Crispr Therapeutics

Silver brings a long-standing familiarity with the company’s internal operations to the role, having joined the organization in October 2018. His tenure has spanned key financial disciplines, including treasury, tax, accounting, and strategic planning. Prior to his work at Crispr, he spent over a decade at Ernst & Young, where he qualified as a certified public accountant.

Under the terms of his new appointment, Silver will earn an annual base salary of $515,000. Regulatory filings with the Securities and Exchange Commission reveal his compensation package also includes eligibility for an annual bonus target of 45% of his base pay, along with a one-time grant of 25,000 restricted stock units.